# A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

> **NCT01706159** · PHASE2 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 20 (actual)

## Conditions studied

- Inflammation
- Ulcerative Colitis

## Interventions

- **DRUG:** catridecacog
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01706159
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Trial screening data did not support the medical hypothesis
- **Last updated:** 2014-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706159, "A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01706159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*